Mortality and Paclitaxel Devices, Data Are Aligning

5 years ago, several prospective randomized studies confirmed paclitaxel coated balloons were safe and effective in femoropopliteal territory. However, a recently published meta-analysis of heterogeneous studies including both paclitaxel coated balloons and drug eluting stents has linked these devices to mortality. In addition, higher doses were associated to higher mortality, both at 2 and 5 years.

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

This new meta-analysis soon to be published in J Am Coll Cardiol seeks to determine whether this association really exists in 1980 patients followed up at 5 years.

Data from 4 randomized independently adjudicated prospective studies, 2 including 1837 patients receiving paclitaxel coated balloons and 2 including 143 control patients receiving uncoated conventional balloons, were included. A thorough analysis of patient baseline characteristics was carried out and followed at long term to prove whether or not the use of paclitaxel had a positive correlation with mortality. Survival rate and dose tercile were taken into account.


Read also: Post TAVR New Onset Left Bundle Branch Block at Long Term: Worth Our Attention?


All efforts were coordinated to shed light on this link that both interventionists and patients are so concerned about, seeing as the latter have already been treated with these devices.

There was no significant association between all-cause mortality and paclitaxel coated balloons at 5-year follow-up (9.3% vs. 11.2%; p=0.399). No deaths were independently adjudicated to these devices.

When dividing patients according to dose tercile, there were no differences between patients receiving the higher dose vs. patients with the lower dose of paclitaxel (p=0.7).

Conclusion

This new meta-analysis shows paclitaxel coated balloons are safe and are not liked to increased mortality, even in patients with higher doses.

Original Title: Mortality Not Correlated With Paclitaxel Exposure An Independent Patient-Level Meta-Analysis.

Reference: Peter A. Schneider et al. J Am Coll Cardiol 2019; Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....